Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy

Clinical translation of novel immunotherapeutic strategies such as chimeric antigen receptor (CAR) T-cells in acute myeloid leukemia (AML) is still at an early stage. Major challenges include immune escape and disease relapse demanding for further improvements in CAR design. To overcome such hurdles...

Full description

Bibliographic Details
Main Authors: Enrico Kittel-Boselli, Karla Elizabeth González Soto, Liliana Rodrigues Loureiro, Anja Hoffmann, Ralf Bergmann, Claudia Arndt, Stefanie Koristka, Nicola Mitwasi, Alexandra Kegler, Tabea Bartsch, Nicole Berndt, Heidi Altmann, Frederick Fasslrinner, Martin Bornhäuser, Michael Philipp Bachmann, Anja Feldmann
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
chimeric antigen receptor (CAR)
tumor immunotherapy
combinatorial gated targeting
acute myeloid leukemia (AML)
Online Access:https://www.mdpi.com/2072-6694/13/19/4785

Internet

https://www.mdpi.com/2072-6694/13/19/4785

Similar Items